CryoPort (NASDAQ:CYRX) Posts Quarterly Earnings Results, Misses Estimates By $0.07 EPS

CryoPort (NASDAQ:CYRX) posted its quarterly earnings results on Thursday. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.07), Zacks reports. CryoPort had a negative net margin of 20.05% and a negative return on equity of 7.20%. The business had revenue of $50.22 million for the quarter, compared to analyst estimates of $48.66 million.

Here are the key takeaways from CryoPort’s conference call:

• Cryoport reported third-quarter revenue of $50.2 million, up 14% year over year, and raised its 2026 continuing-operations revenue outlook to $197 million–$199 million. Management characterized the outlook as prudent, with fourth-quarter growth expected to continue but potential upside.
• Life Sciences Services revenue rose 18%, including 20% growth in commercial cell and gene therapy activity; the company supports 23 commercial therapies and reported a record pipeline of 788 clinical trials, including 99 in Phase III. Management sees the pipeline and rising therapy adoption as drivers of future commercial growth.
• The company posted a second consecutive quarter of positive adjusted EBITDA, at $1.1 million and $1.8 million better year over year. Management expects further operating leverage as new BioServices capabilities come online, while noting that long-term margin targets remain goals rather than current results.
• Life science products revenue increased 8%, supported by animal-health demand and the Fusion freezer line, although management described animal health as cyclical and said China was stable but not a significant growth market. Four expected 2026 therapy application filings have shifted to 2027, while two potential fourth-quarter approvals have FDA decision dates.

CryoPort Trading Up 19.0%

NASDAQ CYRX opened at $19.10 on Friday. The company has a 50 day moving average of $16.98 and a 200-day moving average of $13.46. CryoPort has a 1-year low of $7.61 and a 1-year high of $19.53. The firm has a market cap of $967.42 million, a price-to-earnings ratio of -19.69 and a beta of 1.89.

Analysts Set New Price Targets

CYRX has been the subject of a number of recent research reports. Robert W. Baird set a $26.00 price objective on shares of CryoPort in a research note on Tuesday, October 13th. BTIG Research increased their price target on shares of CryoPort from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Guggenheim increased their price target on shares of CryoPort from $16.00 to $19.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Weiss Ratings upgraded CryoPort from a “sell (d)” rating to a “hold (c-)” rating in a research report on Thursday, October 8th. Finally, Piper Sandler upgraded shares of CryoPort to a “buy” rating in a research note on Tuesday, October 13th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.69.

Key Headlines Impacting CryoPort

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Third-quarter revenue rose 14% year over year to $50.2 million, topping estimates of $48.66 million. Commercial cell and gene therapy revenue grew 20%; Cryoport supported a record 788 global clinical trials and 23 commercially approved therapies. Cryoport Reports Third Quarter 2026 Financial Results
• Positive Sentiment: The company raised its full-year 2026 revenue outlook to $197 million–$199 million, a key catalyst behind the favorable reaction to results. CryoPort Shares Rise After Q3 Revenue Beat, 2026 Guidance Raise
• Positive Sentiment: Analyst actions added support: Needham raised its price target to $28 from $19 and reiterated Buy, while KeyCorp lifted its target to $20 from $17 and maintained an Overweight rating. Needham Adjusts Price Target KeyCorp Rating
• Negative Sentiment: Adjusted earnings were a loss of $0.25 per share, missing consensus estimates of a $0.18–$0.19 loss and widening from a $0.18 loss a year earlier. The earnings shortfall may temper optimism around the revenue growth and raised outlook. CryoPort Reports Q3 Loss, Tops Revenue Estimates

Insiders Place Their Bets

In related news, CEO Jerrell Shelton sold 28,800 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $14.91, for a total transaction of $429,408.00. Following the completion of the sale, the chief executive officer directly owned 1,201,814 shares of the company’s stock, valued at $17,919,046.74. The trade was a 2.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 9.50% of the company’s stock.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) provides temperature-controlled supply chain solutions for the life sciences industry. The company supports the transportation, storage and management of biological materials, including cell and gene therapies, vaccines, biologics, reproductive materials and other temperature-sensitive products.

Its offerings include cryogenic and refrigerated shipping containers, biological material storage, transportation logistics, shipment monitoring and related supply chain management services.